熱門資訊> 正文

Fate Therapeutics任命新首席财务官支持自身免疫项目扩展

2025-10-14 20:15

Fate Therapeutics (NASDAQ:FATE) has appointed Kamal Adawi as chief financial officer, effective October 20, 2025.
Adawi brings over 20 years of financial leadership experience in life sciences, including 10+ years as CFO.
Adawi's expertise aligns with Fate’s strategy to advance iPSC-derived therapies, including FT819 for lupus.

More on Fate Therapeutics

Fate Therapeutics: Recent Update Met With Selling, But Positives Exist
Seeking Alpha’s Quant Rating on Fate Therapeutics
Historical earnings data for Fate Therapeutics
Financial information for Fate Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。